Suppr超能文献

评价胰腺特异性 microRNAs 在大鼠血浆中作为胰腺损伤生物标志物的相对性能。

Evaluation of the Relative Performance of Pancreas-Specific MicroRNAs in Rat Plasma as Biomarkers of Pancreas Injury.

机构信息

Safety Assessment and Laboratory Animal Resources, Merck & Co., Inc., West Point, Pennsylvania 19486.

出版信息

Toxicol Sci. 2020 Jan 1;173(1):5-18. doi: 10.1093/toxsci/kfz184.

Abstract

Drug-induced pancreatic injury (DIPI) has become linked in recent years to many commonly prescribed medications from several pharmacological classes. Diagnosis is currently most often focused on identification of acute pancreatitis and generally based on subjective clinical assessment and serum amylase and lipase enzymatic activity, which have been criticized as being insufficiently sensitive and specific. The lack of novel noninvasive biomarkers of DIPI can impede the advancement of drug candidates through nonclinical development and translation into clinical settings. Pancreas-specific microRNAs (miRNAs) are currently being evaluated as biomarkers of DIPI that may outperform and/or add value to the interpretation of amylase and lipase. To assess the relative performance of these novel miRNAs, a comprehensive evaluation was conducted to determine the sensitivity and specificity of detecting DIPI in rats. Four miRNAs were evaluated (miR-216a-5p, miR-216b-5p, miR-217-5p, and miR-375-3p) in plasma from 10 studies in which rats were treated with known pancreatic toxicants to assess sensitivity, and from 10 different studies in which toxicity was evident in tissues other than pancreas to assess specificity. The candidate miRNA biomarker performance was compared with amylase and lipase, and receiver operator characteristics (ROC) were determined. Analysis of ROCs demonstrated that all four miRNAs outperformed amylase and lipase in monitoring acute pancreatic injury defined as acinar cell degeneration/necrosis. Specifically, miR-217-5p had the highest performance among all biomarkers assessed. The increased sensitivity and specificity of these miRNAs support their use as biomarkers of DIPI, thereby adding value to the interpretation of amylase and lipase measurements in nonclinical studies. The potential for miRNAs to serve as translational biomarkers in the clinic for the monitoring of DIPI is also supported by this investigation.

摘要

药物性胰腺损伤(DIPI)近年来与许多常用的药理学类别中的药物有关。目前,诊断主要集中在急性胰腺炎的识别上,通常基于主观临床评估和血清淀粉酶和脂肪酶的酶活性,这些方法被认为不够敏感和特异性。缺乏新的 DIPI 非侵入性生物标志物可能会阻碍候选药物在非临床开发和转化为临床环境中的进展。胰腺特异性 microRNAs(miRNAs)目前被评估为 DIPI 的生物标志物,它们可能优于(outperform)和/或增加对淀粉酶和脂肪酶的解释价值。为了评估这些新型 miRNA 的相对性能,进行了全面评估,以确定在大鼠中检测 DIPI 的敏感性和特异性。在 10 项研究中评估了 4 种 miRNA(miR-216a-5p、miR-216b-5p、miR-217-5p 和 miR-375-3p)在血浆中的表现,这些研究用已知的胰腺毒物处理大鼠以评估敏感性,在 10 项不同的研究中评估了在胰腺以外的组织中出现毒性的特异性。将候选 miRNA 生物标志物的性能与淀粉酶和脂肪酶进行比较,并确定了接收者操作特征(ROC)。ROC 分析表明,所有 4 种 miRNA 在监测以腺泡细胞变性/坏死定义的急性胰腺损伤方面均优于淀粉酶和脂肪酶。具体而言,miR-217-5p 在所有评估的生物标志物中表现最好。这些 miRNA 的敏感性和特异性的提高支持它们作为 DIPI 的生物标志物的使用,从而增加了非临床研究中对淀粉酶和脂肪酶测量的解释价值。本研究还支持 miRNA 作为临床监测 DIPI 的转化生物标志物的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验